StockMarketWire.com - Cancer and fibrosis drug development group Redx Pharma said its first-half losses halved after it exited administration in November and re-focused its R&D efforts to cut costs.

Pre-tax losses amounted to £4.9m, compared to £11.0m of red ink a year earlier.

At 31 March, the company had a cash balance of £10.3m.




At 8:39am: [LON:REDX] Redx Pharma Plc share price was 0p at 13.5p



Story provided by StockMarketWire.com